Pertuzumab biosimilar is under clinical development by Organon & Co and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Pertuzumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pertuzumab biosimilar overview
Pertuzumab biosimilar (HLX-11) is under development for the treatment of HER2-positive, metastatic, or unresectable locally recurrent breast cancer. It is administered through intravenous route and targets the extracellular domain of human epidermal growth factor receptor 2 (HER2).
Organon & Co overview
Organon & Co (Organon) is a healthcare company. The company discovers and develops biosimilars and medicines. It provides medicines and solutions for various conditions including respiratory, cardiovascular, dermatology, non-opioid pain, women’s health and others. The company’s products include mometasone furoate inhalation powder, follitropin beta injection, alendronate sodium, acetate injection, chorionic gonadotropin and others. It conducts patient assistance and Organon access program, which provide free medicines to individuals. Organon markets its products through a network of distribution channels in domestic and overseas markets. It collaborates with pharmaceutical and biopharmaceutical businesses to market its products. Organon is headquartered in Jersey City, New Jersey, the US.
For a complete picture of Pertuzumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
